Dalvir Gill is a Cardiology physician affiliated with Vincennes University. OpenAlex indexes 55 publications with 471 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 S 7th St
Vincennes, IN 475911038
Telephone
812-885-3243Provider last certified this registry record 8 May 2023.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20257 payments
- Actelion Pharmaceuticals US, Inc.Program year20255 payments
- Novo Nordisk IncProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.1%Beta blocker19.3%Metoprolol Succinate78%Bisoprolol Fumarate14%Metoprolol Tartrate5%Carvedilol3%Part D<11 patientsStatin13.7%Rosuvastatin Calcium57%Atorvastatin Calcium39%Pravastatin Sodium3%Part D<11 patients+ 12 more classes in this area
Blood & clotting
16.2%Factor Xa inhibitor7.6%Eliquis65%Xarelto35%Part D≥36 patientsP2Y12 inhibitor7.4%Clopidogrel100%Part D≥85 patients+ 2 more classes in this area
Metabolism & gastrointestinal
3.3%SGLT2 inhibitor1.6%Jardiance63%Farxiga37%Part D<11 patientsPotassium supplement1.2%Potassium Chloride100%Part D≥11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A-70 | Double Jeopardy: Comparative Mortality Trends in CKD-Linked Acute Myocardial Infarction (AMI) Versus Standalone AMI Among Obese Adults in the United States
Journal of the Society for Cardiovascular Angiography & Interventions
2025 - A-106 | Diabetes Complicates the Shock: 22-Year Mortality Trends in Cardiogenic Shock with and without Diabetes in the United States
Journal of the Society for Cardiovascular Angiography & Interventions
2025 - Proclamations and provocations: Decolonising curriculum in education research and professional practice
Equity in Education & Society
2022 - TCT-439 Cardiovascular Outcomes of Hospital Frailty Index on TAVR and Associated Readmissions: A Nationwide Readmission Database Analysis
Journal of the American College of Cardiology
2022 - Usefulness of acetazolamide in the management of diuretic resistance
Baylor University Medical Center Proceedings
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”